AveX­is shares soar af­ter it out­lines FDA’s sup­port for a loom­ing piv­otal study on SMA

AveX­is CEO Sean Nolan

Shares of AveX­is $AVXS ripped high­er af­ter the mar­ket close on Tues­day af­ter the gene ther­a­py biotech out­lined the FDA’s ac­cep­tance of a small, sin­gle arm piv­otal study for rare cas­es of spinal mus­cu­lar at­ro­phy Type 1 (SMA).

Ac­cord­ing to the Chica­go-based biotech, reg­u­la­tors signed off on a 20-pa­tient study that would use a his­tor­i­cal com­par­i­son for eval­u­at­ing ef­fi­ca­cy. And that lays a straight path to a piv­otal study now slat­ed to be­gin in the first half of a loom­ing 2017.

AveX­is shares shot up 25% on the tri­al plans.

Here’s the sum­ma­ry:

At the Type B meet­ing and in the meet­ing min­utes, the FDA ac­knowl­edged the com­pa­ny’s ra­tio­nale for a sin­gle-arm piv­otal study and pro­vid­ed a num­ber of con­struc­tive sug­ges­tions to help op­ti­mize such a tri­al de­sign. The FDA al­so in­di­cat­ed its pref­er­ence for a de­sign with co-pri­ma­ry end­points con­sist­ing of a mea­sure of de­vel­op­men­tal mile­stone achieve­ment (such as sit­ting unas­sist­ed) along with a clin­i­cal­ly mean­ing­ful mea­sure of sur­vival (such as time to an “event” as de­scribed above). Based on FDA’s sug­ges­tions as well as oth­er ex­pert in­put, AveX­is con­tin­ues to eval­u­ate a num­ber of the de­tails of the tri­al de­sign. More spe­cif­ic in­for­ma­tion will be made avail­able at the time the study is ini­ti­at­ed, which is ex­pect­ed in the first half of 2017.

“We be­lieve the Type B meet­ing had a pos­i­tive tone, with FDA of­fer­ing a num­ber of con­struc­tive sug­ges­tions which we be­lieve will bet­ter en­able im­ple­men­ta­tion of a piv­otal study de­sign that is most ap­pro­pri­ate for the pa­tients suf­fer­ing from this dev­as­tat­ing dis­ease,” said AveX­is CEO Sean Nolan in a state­ment. “With the feed­back need­ed from the FDA to move for­ward with our piv­otal tri­al, we plan to pro­ceed as ex­pe­di­tious­ly as pos­si­ble to be­gin the study in the first half of 2017.”

Not on­ly that, the FDA — which ap­pears to be quite ac­com­mo­dat­ing in AveX­is’s sum­ma­ry — is al­so will­ing to con­sid­er an ap­proval on the Phase I study. At least one an­a­lyst says these de­vel­op­ments could pose a prob­lem for Bio­gen and Io­n­is, which are part­nered on nusin­ersen for SMA. Notes Jef­feries’ Bri­an Abra­hams:

While ear­ly da­ta for AVXS’s AVXS-101 has looked promis­ing in SMA, it is hard to com­pare be­tween treat­ments and BI­IB re­tains a first mover ad­van­tage that could po­ten­tial­ly lim­it up­take of ‘101. Ad­di­tion­al­ly, nusin­ersen is al­so be­ing ex­plored in stud­ies of Type 2/3 SMA, which rep­re­sent ad­di­tion­al sig­nif­i­cant mar­ket op­por­tu­ni­ties, and the pos­si­bil­i­ty of broad ini­tial ap­proval across all sub­types re­mains; in con­trast, AVXS is just be­gin­ning to ex­plore such ad­di­tion­al SMA pop­u­la­tions. Sys­temic ad­min­is­tra­tion of AVXS-101 could, how­ev­er, of­fer greater con­ve­nience, at least in Type 1 pts. We would not rule out the pos­si­bil­i­ty the ther­a­pies could be used in the same pts, though pric­ing could be an is­sue. We cur­rent­ly mod­el a 2017 nusin­ersen launch with prob­a­bil­i­ty-ad­just­ed rev­enues po­ten­tial­ly reach­ing $1.5B by 2025.

Oxitec biologist releases genetically modified mosquitoes in Piracicaba, Brazil in 2016 [credit: Getty Images]

In­trex­on unit push­es back against claims its GM mos­qui­toes are mak­ing dis­ease-friend­ly mu­tants

When the hysteria of Zika transmission sprang into the American zeitgeist a few years ago, UK-based Oxitec was already field-testing its male Aedes aegypti mosquito, crafted to possess a gene engineered to obliterate its progeny long before maturation.

But when a group of independent scientists evaluated the impact of the release of these genetically-modified mosquitoes in a trial conducted by Oxitec in Brazil between 2013 and 2015, they found that some of the offspring had managed to survive — prompting them to speculate what impact the survivors could have on disease transmission and/or insecticide resistance.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 60,000+ biopharma pros reading Endpoints daily — and it's free.

[via AP Images]

Pur­due threat­ens to walk away from set­tle­ment, asks to pay em­ploy­ees mil­lions in bonus­es

There are two updates on the lawsuit against Purdue Pharma over its role in fueling the opioid epidemic, as the Sackler family threatens to walk away from their pledge to pay out $3 billion if a bankruptcy judge does not stop outstanding state lawsuits against them. At the same time, the company has asked permission to pay millions in bonuses to select employees.

Purdue filed for chapter 11 bankruptcy this week as part of its signed resolution to over 2,000 lawsuits. The deal would see the Sackler family that owns Purdue give $3 billion from their personal wealth and the company turned into a trust committed to curbing and reversing overdoses.

As Nas­daq en­rolls the fi­nal batch of 2019 IPOs, how have the num­bers com­pared to past years?

IGM Biosciences’ upsized IPO haul, coming after SpringWorks’ sizable public debut, has revved up some momentum for the last rush of biotech IPOs in 2019.

With 39 new listings on the books and roughly two more months to go before winding down, Nasdaq’s head of healthcare listings Jordan Saxe sees the exchange marking 50 to 60 biopharma IPOs for the year.

“December 15 is usually the last possible day that companies will price,” he said, as companies get ready for business talks at the annual JP Morgan Healthcare Conference in January.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 60,000+ biopharma pros reading Endpoints daily — and it's free.

Aerial view of Genentech's campus in South San Francisco [Credit: Getty]

Genen­tech sub­mits a plan to near­ly dou­ble its South San Fran­cis­co foot­print

The sign is still there, a quaint reminder of whitewashed concrete not 5 miles from Genentech’s sprawling, chrome-and-glass campus: South Francisco The Industrial City. 

The city keeps the old sign, first erected in 1923, as a tourist site and a kind of civic memento to the days it packed meat, milled lumber and burned enough steel to earn the moniker “Smokestack of the Peninsula.” But the real indication of where you are and how much has changed both in San Francisco and in the global economy since a couple researchers and investors rented out an empty warehouse 40 years ago comes in a far smaller blue sign, resembling a Rotary Club post, off the highway: South San Francisco, The Birthplace of Biotech.

A fa­vorite in Alex­ion’s C-suite is leav­ing, and some mighty sur­prised an­a­lysts aren’t the least bit hap­py about it

Analysts hate to lose a biotech CFO they’ve come to trust and admire — especially if they’re being blindsided by a surprise exit.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 60,000+ biopharma pros reading Endpoints daily — and it's free.

David Grainger [file photo]

'Dis­con­nect the bas­tard­s' — one biotech's plan to break can­cer cell­s' uni­fied de­fens­es

Chemotherapy and radiotherapy are the current gladiators of cancer treatment, but they come with well-known limitations and side-effects. The emergence of immunotherapy — a ferocious new titan in oncologist’s toolbox — takes the brakes off the immune system to kill cancer cells with remarkable success in some cases, but the approach is not always effective. What makes certain forms of cancer so resilient? Scientists may have finally pieced together a tantalizing piece of the puzzle, and a new biotech is banking on a new approach to fill the gap.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 60,000+ biopharma pros reading Endpoints daily — and it's free.

While No­var­tis ban­ish­es Zol­gens­ma scan­dal scars — Bio­gen goes on a Spin­raza 'of­fen­sive'

While Novartis painstakingly works to mop up the stench of the data manipulation scandal associated with its expensive gene therapy for spinal muscular atrophy (SMA) Zolgensma— rival Biogen is attempting to expand the use of its SMA therapy, Spinraza. 

The US drugmaker $BIIB secured US approval for Spinraza for use in the often fatal genetic disease in 2016. The approval covered a broad range of patients with infantile-onset (most likely to develop Type 1) SMA. 

Jason Kelly. Mike Blake/Reuters via Adobe

Eye­ing big ther­a­peu­tic push, Gink­go bags $290M to build a cell pro­gram­ming em­pire

Ginkgo Bioworks is on a roll. Days after publicizing a plan to nurture new startups via partnerships with accelerators Y Combinator and Petri, the Boston biotech says it has raised another $290 million for its cell programming platform to reach further and wider.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 60,000+ biopharma pros reading Endpoints daily — and it's free.

UP­DAT­ED: Speak­er Nan­cy Pelosi to un­veil bill for fed­er­al­ly ne­go­ti­at­ed drug prices

After months of buzz from both sides of the aisle, Speaker Nancy Pelosi will today introduce her plan to allow the federal government to negotiate prices for 250 prescription drugs, setting up a showdown with a pharmaceutical industry working overtime to prevent it.

The need to limit drug prices is a rare point of agreement between President Trump and Democrats, although the president has yet to comment on the proposal and will likely face pressure to back a more conservative option or no bill at all. Republican Senator Chuck Grassley is reportedly lobbying his fellow party members on a more modest proposal he negotiated with Democratic Senator Ron Wyden in July.